Please assess the completion status of the following clinical trial:

Trial Title: Addressing Post Cessation Weight Gain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be considered for inclusion if they meet all of the following~1. ≥18 years and ≤65 years of age;~2. smoked ≥10 cigarettes/day for the past 6 months;~3. Body Mass Index of 27-39.9 kg/m2;~4. motivated to stop smoking;~5. weight concerned as shown with the Weight Concern Scale;~6. able to participate fully in all aspects of the study;~7. understand and signed the study informed consent.~8. Subject is in good health as determined by the clinical investigators.~Exclusion Criteria:~Subjects will be ineligible for participation if they have any of the following:~1. current nonspecific suicidal thoughts or a lifetime history of a suicidal attempt (defined by the Columbia-Suicide Severity Rating Scale as a potentially self-injurious act committed with at least some wish to die, as a result of act.);~2. current moderate or severe depression as assessed by a score of ≥16 on the Center for Epidemiology Studies-Depression;~3. a lifetime history of psychosis, bipolar disorder or schizophrenia;~4. use of anti-psychotic medication within the past 30 days;~5. use of weight-loss medications within the past 30 days or current participation in a program specifically designed to help with weight loss;~6. weight fluctuations of 20 pounds or more in the past 6 months (self-report);~7. use of any treatments for tobacco dependence within the past 30 days;~8. use of an investigational drug within the past 30 days;~9. recent history (past 3 months) of abuse of or dependence on a substance other than tobacco. Including: heavy alcohol consumption (If male, drinking \> 4 alcoholic beverages per day for past month and if female, drinking \> 3 alcoholic beverages per day for past month); use of cocaine, heroin, club drugs (i.e., methylenedioxymethamphetamine(MDMA)/ecstasy), methamphetamine, or hallucinogens (e.g., LSD) at any time during the past 3 months; and use of marijuana on a weekly basis for the past 3 months~10. current use of triptans, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRI), selective serotonin-norepinephrine re-uptake inhibitors (SNRI), dextromethorphan, tricyclic antidepressants (TCA), bupropion, lithium, tramadol, tryptophan, and St. John's Wort, or any other medication known to involve the serotonergic neurotransmitter system (see human subjects section);~11. uncontrolled hypertension (systolic \>160 mm Hg and/or diastolic \>100 mm Hg) documented on 2 separate occasions;~12. current use of medications known to interact with varenicline or lorcaserin. These can include benzodiazepines, narcotics, anti-epileptics;~13. another household member or relative participating in the study;~14. known diabetes;~15. a known allergy to varenicline or lorcaserin.~16. Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded. Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine device, surgical sterilization, and abstinence.~17. Has an unstable medical condition as determined by the physician investigator~18. Subject describes having a medical history of: a) unstable angina; b) myocardial infarction within the past 3 months; c) coronary angioplasty or d) an untreated cardiac dysrhythmia.~19. Subject currently has cancer \[excluding non-melanoma skin cancer\] not in remission~20. Known history of seizures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Varenicline plus placebo (Type: PLACEBO_COMPARATOR): Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
- Varenicline plus lorcaserin (Type: EXPERIMENTAL): Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).